Novartis’ Sandoz gains EC approval for biosimilar Hyrimoz across multiple therapeutic areas

pharmanewsdaily- July 29, 2018

In a significant advancement for biopharmaceuticals, Novartis' division Sandoz has secured approval from the European Commission (EC) for Hyrimoz (adalimumab), a biosimilar to AbbVie’s Humira. ... Read More

Amgen’s Parsabiv receives EC approval in secondary hyperparathyroidism

pharmanewsdaily- November 13, 2016

Amgen Inc., a leading American biopharmaceutical company, has achieved a significant milestone with the approval of its drug Parsabiv (etelcalcetide) by the European Commission (EC) ... Read More